Adedayo A. Onitilo

6.1k total citations · 2 hit papers
167 papers, 3.7k citations indexed

About

Adedayo A. Onitilo is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Adedayo A. Onitilo has authored 167 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Oncology, 33 papers in Surgery and 32 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Adedayo A. Onitilo's work include Global Cancer Incidence and Screening (22 papers), Breast Cancer Treatment Studies (19 papers) and Cancer Treatment and Pharmacology (14 papers). Adedayo A. Onitilo is often cited by papers focused on Global Cancer Incidence and Screening (22 papers), Breast Cancer Treatment Studies (19 papers) and Cancer Treatment and Pharmacology (14 papers). Adedayo A. Onitilo collaborates with scholars based in United States, Australia and Nigeria. Adedayo A. Onitilo's co-authors include Jessica M. Engel, Suhail A.R. Doi, Rachel V. Stankowski, Bickol N. Mukesh, Robert T. Greenlee, Erin J. Aiello Bowles, Heather Spencer Feigelson, Ingrid Glurich, Tom Barney and Richard M. Single and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Adedayo A. Onitilo

151 papers receiving 3.6k citations

Hit Papers

Breast Cancer Subtypes Ba... 2009 2026 2014 2020 2009 2012 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival
    2009 585 citations Adedayo A. Onitilo, Jessica M. Engel et al. Clinical Medicine & Research profile →
  2. Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study
    2012 411 citations Erin J. Aiello Bowles, Heather Spencer Feigelson et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Adedayo A. Onitilo 1.7k 947 775 619 551 167 3.7k
Mourad Tighiouart 1.7k 1.0× 700 0.7× 1.6k 2.1× 930 1.5× 341 0.6× 152 5.0k
Ondřej Topolčan 1.6k 0.9× 1.1k 1.1× 1.3k 1.7× 1.0k 1.7× 220 0.4× 254 4.2k
Shailendra Verma 2.7k 1.5× 846 0.9× 781 1.0× 1.3k 2.0× 322 0.6× 177 4.8k
Judy Zhong 1.2k 0.7× 494 0.5× 1.2k 1.5× 372 0.6× 458 0.8× 146 3.8k
Xiudong Lei 1.9k 1.1× 1.3k 1.3× 577 0.7× 1.7k 2.7× 266 0.5× 159 4.8k
Jane Warwick 2.1k 1.2× 752 0.8× 361 0.5× 1.1k 1.7× 258 0.5× 102 4.6k
Steve Scoppa 1.7k 1.0× 515 0.5× 803 1.0× 827 1.3× 197 0.4× 17 3.7k
P. Pronzato 2.5k 1.5× 1.1k 1.2× 731 0.9× 884 1.4× 242 0.4× 231 4.4k
Mario Roselli 2.3k 1.4× 711 0.8× 1.4k 1.8× 1.1k 1.7× 381 0.7× 240 5.3k
Hyunsoon Cho 2.8k 1.6× 868 0.9× 1.5k 1.9× 1.6k 2.5× 314 0.6× 83 6.8k

Countries citing papers authored by Adedayo A. Onitilo

Since Specialization
Citations

This map shows the geographic impact of Adedayo A. Onitilo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adedayo A. Onitilo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adedayo A. Onitilo more than expected).

Fields of papers citing papers by Adedayo A. Onitilo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adedayo A. Onitilo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adedayo A. Onitilo. The network helps show where Adedayo A. Onitilo may publish in the future.

Co-authorship network of co-authors of Adedayo A. Onitilo

This figure shows the co-authorship network connecting the top 25 collaborators of Adedayo A. Onitilo. A scholar is included among the top collaborators of Adedayo A. Onitilo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adedayo A. Onitilo. Adedayo A. Onitilo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Abdulmajeed, Jazeel, Zumin Shi, Manar E. Abdel‐Rahman, et al.. (2025). Bariatric metabolic surgery and cancer risk: Target trial emulation using iterative time distribution matching. Biomolecules and Biomedicine. 26(6). 933–942.
2.
Patel, Sandip Pravin, Young Kwang Chae, Shiruyeh Schokrpur, et al.. (2025). Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma. npj Precision Oncology. 9(1). 24–24. 1 indexed citations
3.
Wen, Zhi, Yidan Wang, Terrie Kitchner, et al.. (2025). Inhibition of FOXM1 Synergizes with BH3 Mimetics Venetoclax and Sonrotoclax in Killing Multiple Myeloma Cells through Repressing MYC Pathway. Advanced Science. 12(37). e08822–e08822.
4.
Owonikoko, Taofeek K., Alberto Chiappori, Ryan D. Gentzler, et al.. (2024). Alisertib in patients with extensive-stage small-cell lung cancer: The phase 2 ALISCA-Lung1 study.. Journal of Clinical Oncology. 42(16_suppl). TPS8128–TPS8128. 1 indexed citations
5.
Balogun, Onyinye, Omolola Salako, Omoruyi Credit Irabor, et al.. (2024). Development and implementation of a 3d-HDR brachytherapy program for cervical cancer in a sub-Saharan African centre. Brachytherapy. 24(2). 258–264.
6.
Peterson, Derick R., Richard F. Dunne, Judith O. Hopkins, et al.. (2024). Nutritional impairment, psychological health and quality of life among older adults with advanced cancer: A secondary analysis of a randomized clinical trial. Cancer Medicine. 13(12). e7348–e7348. 2 indexed citations
7.
Hu, Chengping, Helen J. Ross, David Kozono, et al.. (2024). Concurrent Chemoradiation ± Atezolizumab (atezo) in Limited-Stage Small Cell Lung Cancer (LS-SCLC): Results of NRG Oncology/Alliance LU005. International Journal of Radiation Oncology*Biology*Physics. 120(2). S2–S2. 23 indexed citations
8.
O’Hara, Mark H., Opeyemi A. Jegede, Mark A. Dickson, et al.. (2024). Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C. Clinical Cancer Research. 31(1). 56–64. 1 indexed citations
9.
McBane, Robert D., Charles L. Loprinzi, Tyler Zemla, et al.. (2024). Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial. Journal of Thrombosis and Haemostasis. 22(6). 1704–1714. 20 indexed citations
10.
Abdulmajeed, Jazeel, et al.. (2023). Use of conditional estimates of effect in cancer epidemiology: An application to lung cancer treatment. Cancer Epidemiology. 88. 102521–102521. 1 indexed citations
11.
McBane, Robert D., Charles L. Loprinzi, Shaker R. Dakhil, et al.. (2023). LB 02.1 Extending Venous Thromboembolism Secondary Prevention with Apixaban in Cancer Patients. The EVE Trial. Research and Practice in Thrombosis and Haemostasis. 7. 100293–100293. 2 indexed citations
12.
13.
14.
Connolly, Roisín M., Fengmin Zhao, Kathy D. Miller, et al.. (2021). E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group. Journal of Clinical Oncology. 39(28). 3171–3181. 76 indexed citations
15.
Ruddy, Kathryn J., Jennifer Le‐Rademacher, Mario E. Lacouture, et al.. (2019). Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511I); an ACCRU trial. The Breast. 48. 89–97. 38 indexed citations
16.
Burnside, Elizabeth S., Jie Liu, Yirong Wu, et al.. (2015). Comparing Mammography Abnormality Features to Genetic Variants in the Prediction of Breast Cancer in Women Recommended for Breast Biopsy. Academic Radiology. 23(1). 62–69. 10 indexed citations
17.
Onitilo, Adedayo A., Rachel V. Stankowski, Jessica M. Engel, et al.. (2013). Type 2 diabetes mellitus, glycemic control, and cancer risk. European Journal of Cancer Prevention. 23(2). 134–140. 59 indexed citations
18.
Goddard, Katrina A.B., Erin J. Aiello Bowles, Heather Spencer Feigelson, et al.. (2012). Utilization of HER2 genetic testing in a multi-institutional observational study.. PubMed. 18(11). 704–12. 12 indexed citations
19.
20.
Rocque, Gabrielle B., Adedayo A. Onitilo, Jessica M. Engel, et al.. (2011). Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity. Breast Cancer Research and Treatment. 131(2). 713–721. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mourad Tighiouart Breakdown of academic impact, for papers by Ondřej Topolčan Breakdown of academic impact, for papers by Shailendra Verma Breakdown of academic impact, for papers by Judy Zhong Breakdown of academic impact, for papers by Xiudong Lei Breakdown of academic impact, for papers by Jane Warwick Breakdown of academic impact, for papers by Steve Scoppa Breakdown of academic impact, for papers by P. Pronzato Breakdown of academic impact, for papers by Mario Roselli Breakdown of academic impact, for papers by Hyunsoon Cho
Rankless by CCL
2026